These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21334067)

  • 1. Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation.
    Laurenti L; De Padua L; Battendieri R; Tarnani M; Sica S; Blasi MA; Savino G; Leone G
    Leuk Res; 2011 May; 35(5):682-4. PubMed ID: 21334067
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of intraorbital injection of rituximab for treatment of primary ocular adnexal lymphoma: a pilot study.
    Savino G; Battendieri R; Balia L; Colucci D; Larocca LM; Laurenti L; De Padua L; Blasi MA; Balestrazzi E
    Cancer Sci; 2011 Aug; 102(8):1565-7. PubMed ID: 21564418
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections.
    Savino G; Battendieri R; Gari M; Caputo CG; Laurenti L; Blasi MA
    J Cancer Res Clin Oncol; 2013 Jul; 139(7):1251-5. PubMed ID: 23625184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intralesional and intravenous treatment of cutaneous B-cell lymphomas with the monoclonal anti-CD20 antibody rituximab: report and follow-up of eight cases.
    Kerl K; Prins C; Saurat JH; French LE
    Br J Dermatol; 2006 Dec; 155(6):1197-200. PubMed ID: 17107389
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma.
    Peñate Y; Hernández-Machín B; Pérez-Méndez LI; Santiago F; Rosales B; Servitje O; Estrach T; Fernández-Guarino M; Calzado L; Acebo E; Gallardo F; Salar A; Izu R; Ortiz-Romero PL; Pujol RM; Fernández-de-Misa R
    Br J Dermatol; 2012 Jul; 167(1):174-9. PubMed ID: 22356294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intralesional rituximab: a new therapeutic approach for patients with conjunctival lymphomas.
    Ferreri AJ; Govi S; Colucci A; Crocchiolo R; Modorati G
    Ophthalmology; 2011 Jan; 118(1):24-8. PubMed ID: 20709407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systemic Rituximab Immunotherapy in the Management of Primary Ocular Adnexal Lymphoma: Single Institution Experience.
    Tuncer S; Tanyıldız B; Basaran M; Buyukbabani N; Dogan O
    Curr Eye Res; 2015; 40(8):780-5. PubMed ID: 25247376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of rituximab treatment in patients with progressive transformation of germinal centers after Hodgkin lymphoma in complete remission post-induction chemotherapy and radiotherapy.
    Picardi M; Zeppa P; Ciancia G; Pettinato G; Grimaldi F; Fabbricini R; Mainolfi C; Pane F
    Leuk Lymphoma; 2011 Nov; 52(11):2082-9. PubMed ID: 21663508
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficiency therapy with rituximab in patients with non-Hodgkin's lymphomas].
    Kriachok IA; Filonenko KS; Gubareva GO; Tytorenko IB; Novosad OI; Kadnikova TV; Aleksik OM; Martynchyk AV; Kushchevyĭ ÉV; Pastushenko IaV; Kutsenko LB
    Lik Sprava; 2011; (1-2):117-21. PubMed ID: 21954645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab.
    Yan M; Dong Z; Zhao F; Chauncey T; Deauna-Limayo D; Wang-Rodriguez J; Liu D; Wang HY; Pilz R
    Eur J Haematol; 2014 Jul; 93(1):77-80. PubMed ID: 24528507
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intralesional therapy with anti-CD20 monoclonal antibody rituximab: local and systemic efficacy in primary cutaneous B-cell lymphoma.
    Roguedas AM; Watier H; Paintaud G; de Muret A; Vaillant L; Machet L
    Br J Dermatol; 2005 Mar; 152(3):541-4. PubMed ID: 15787825
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for low-grade non-hodgkin secondary lymphoma of the orbit.
    Esmaeli B; Murray JL; Ahmadi MA; Naderi A; Singh S; Romaguera J; White CA; McLaughlin P
    Arch Ophthalmol; 2002 Sep; 120(9):1225-7. PubMed ID: 12215104
    [No Abstract]   [Full Text] [Related]  

  • 13. [New treatment for orbital non-Hodgkin's lymphoma: 2 cases treated with rituximab].
    Benabid L; Desablens B; Defossez T; Malthieu D; Milazzo S; Turut P
    J Fr Ophtalmol; 2005 Sep; 28(7):769-71. PubMed ID: 16208229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the CD20 and CXCR4 pathways in non-hodgkin lymphoma with rituximab and high-affinity CXCR4 antagonist BKT140.
    Beider K; Ribakovsky E; Abraham M; Wald H; Weiss L; Rosenberg E; Galun E; Avigdor A; Eizenberg O; Peled A; Nagler A
    Clin Cancer Res; 2013 Jul; 19(13):3495-507. PubMed ID: 23637121
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma.
    Heinzerling L; Dummer R; Kempf W; Schmid MH; Burg G
    Arch Dermatol; 2000 Mar; 136(3):374-8. PubMed ID: 10724200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.
    Tran L; Baars JW; de Boer JP; Hoefnagel CA; Beijnen JH; Huitema AD
    Hum Antibodies; 2011; 20(1-2):37-40. PubMed ID: 21558622
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intralesional rituximab for cutaneous B-cell lymphoma.
    Paul T; Radny P; Kröber SM; Paul A; Blaheta HJ; Garbe C
    Br J Dermatol; 2001 Jun; 144(6):1239-43. PubMed ID: 11422050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intralesional rituximab for primary iris lymphoma.
    Demirci H; Grant JS; Elner VM
    JAMA Ophthalmol; 2015 Jan; 133(1):104-5. PubMed ID: 25211092
    [No Abstract]   [Full Text] [Related]  

  • 19. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of intrathecal rituximab in children with B cell lymphoid CD20+ malignancies: An international retrospective study.
    Ceppi F; Weitzman S; Woessmann W; Davies K; Lassaletta A; Reismüller B; Mellgren K; Uyttebroeck A; Maia I; Abdullah S; Miakova N; Glaser D; Cohn R; Abla O; Attarbaschi A; Alexander S
    Am J Hematol; 2016 May; 91(5):486-91. PubMed ID: 26872652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.